BBP vs SBIO

BBPAVirtus Biotech ETF

SBIOCALPS Medical Breakthroughs ETF

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

SBIO SBIO goes at biotech through a purpose-built medical breakthroughs index instead of the household benchmarks, spreading roughly 100 drug developers across one basket. A specialist route, priced at the category's middle.

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

SBIO The fund seeks investment results that generally track, before fees and expenses, the performance of the S-Network Medical Breakthroughs Index (PMBI).

Why people hold it

• BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
• 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
• Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
• One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

• SBIO Tracks the S-Network Medical Breakthroughs Index, a dedicated rules-based basket rather than the standard biotech benchmarks most funds in the group follow.
• Roughly 100 holdings, so no single drug readout carries the whole fund.
• The 0.50% expense ratio sits right at the median for biotech and genomics funds. No premium charged for the narrower mandate.
• Trading since 2014, giving it a decade-plus of live operating history through several biotech cycles.

Worth knowing

• BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
• Income is not the point here. The fund has not been paying distributions, so the return story is price.
• An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

• SBIO Thinly traded next to the giants of the category, so spreads and limit orders matter more here than with the household names.
• Several funds in the same biotech cohort screen stronger overall, and some cost less: IBBQ at 0.19% and XBI at 0.35% versus SBIO's 0.50%.
• Not an income vehicle. Whatever this fund does, it does through the share prices of the drug developers it holds.

Full BBP profile⁠

Full SBIO profile⁠